1. Kennedy, AL, Shimamura, A. Genetic predisposition to MDS: clinical features and clonal evolution. Blood 2019; 133: 1071–1085.
Google Scholar | Crossref | Medline2. Arber, DA, Orazi, A, Hasserjian, R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–2405.
Google Scholar | Crossref | Medline | ISI3. Maciejewski, JP, Padgett, RA, Brown, AL, et al. DDX41-related myeloid neoplasia. Semin Hematol 2017; 54: 94–97.
Google Scholar | Crossref | Medline4. Obrochta, E, Godley, LA. Identifying patients with genetic predisposition to acute myeloid leukemia. Best Pract Res Clin Haematol 2018; 31: 373–378.
Google Scholar | Crossref | Medline5. Yasuda, T, Sanada, M, Nishijima, D, et al. Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study. Cancer Sci 2020; 111: 3367–3378.
Google Scholar | Crossref | Medline6. Andreou, AZ. DDX41: a multifunctional DEAD-box protein involved in pre-mRNA splicing and innate immunity. Biol Chem 2021; 402: 645–651.
Google Scholar | Crossref | Medline7. Weinreb, JT, Ghazale, N, Pradhan, K, et al. Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production. Dev Cell 2021; 56: 627–640.e625.
Google Scholar | Crossref | Medline8. Weinreb, JT, Gupta, V, Sharvit, E, et al. Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish. Haematologica. Epub ahead of print 25 March 2021. DOI: 10.3324/haematol.2020.257246.
Google Scholar | Crossref | Medline9. Cheah, JJC, Hahn, CN, Hiwase, DK, et al. Myeloid neoplasms with germline DDX41 mutation. Int J Hematol 2017; 106: 163–174.
Google Scholar | Crossref | Medline10. Klco, JM, Mullighan, CG. Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nat Rev Cancer 2021; 21: 122–137.
Google Scholar | Crossref | Medline11. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
Google Scholar | Crossref | Medline12. Polprasert, C, Schulze, I, Sekeres, MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer cell 2015; 27: 658–670.
Google Scholar | Crossref | Medline13. Sanderson, S, Tatt, ID, Higgins, JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36: 666–676.
Google Scholar | Crossref | Medline | ISI14. Cardoso, SR, Ryan, G, Walne, AJ, et al. Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia 2016; 30: 2083–2086.
Google Scholar | Crossref | Medline15. Lewinsohn, M, Brown, AL, Weinel, LM, et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood 2016; 127: 1017–1023.
Google Scholar | Crossref | Medline16. Quesada, AE, Routbort, MJ, DiNardo, CD, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol 2019; 94: 757–766.
Google Scholar | Medline17.  Sébert, M, Passet, M, Raimbault, A, et al. Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood 2019; 134: 1441–1444.
Google Scholar | Crossref | Medline18. Bannon, SA, Routbort, MJ, Montalban-Bravo, G, et al. Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Front Oncol 2020; 10: 582213.
Google Scholar | Crossref | Medline19. Polprasert, C, Takeda, J, Niparuck, P, et al. Novel DDX41 variants in Thai patients with myeloid neoplasms. Int J Hematol 2020; 111: 241–246.
Google Scholar | Crossref | Medline20. Qu, S, Li, B, Qin, T, et al. Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations. Br J Haematol 2020; 192: 1006–1010.
Google Scholar | Crossref | Medline21. Choi, EJ, Cho, YU, Hur, EH, et al. Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica. Epub ahead of print 25 February 2021. DOI: 10.3324/haematol.2020.270553.
Google Scholar | Crossref22. DiNardo, CD, Bannon, SA, Routbort, M, et al. Evaluation of patients and families with concern for predispositions to hematologic malignancies within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk 2016; 16: 417–428.e412.
Google Scholar | Crossref | Medline23. Li, R, Sobreira, N, Witmer, PD, et al. Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia. Haematologica 2016; 101: e228–e231.
Google Scholar | Crossref | Medline24. Drazer, MW, Kadri, S, Sukhanova, M, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv 2018; 2: 146–150.
Google Scholar | Crossref | Medline25. Vairo, FPE, Ferrer, A, Cathcart-Rake, E, et al. Novel germline missense DDX41 variant in a patient with an adult-onset myeloid neoplasm with excess blasts without dysplasia. Leuk Lymphoma 2019; 60: 1337–1339.
Google Scholar | Crossref | Medline26. Weinberg, OK, Kuo, F, Calvo, KR. Germline predisposition to hematolymphoid neoplasia. Am J Clin Pathol 2019; 152: 258–276.
Google Scholar | Crossref | Medline27. Abou Dalle, I, Kantarjian, H, Bannon, SA, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol 2020; 95: 227–229.
Google Scholar | Crossref | Medline28. Chen, J, Qu, SQ, Qin, TJ, et al. [Lenalidomide for myelodysplastic syndrome with excess blasts with germline DDX41 mutation: a case report and literatures review]. Zhonghua xue ye xue za zhi 2020; 41: 857–860.
Google Scholar | Medline29.  Kim, B, Yun, W, Lee, ST, et al. Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia. Sci Rep 2020; 10: 14297.
Google Scholar | Crossref | Medline30. Andrés-Zayas, C, Suárez-González, J, Rodríguez-Macías, G, et al. Clinical utility of targeted next generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. Mol Oncol. Epub ahead of print 3 February 2021. DOI: 10.1002/1878-0261.12921.
Google Scholar | Crossref | Medline31. Fazio, F, Quintini, M, Carmosino, I, et al. New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. Leuk Lymphoma. Epub ahead of print 9 April 2021. DOI: 10.1080/10428194.2021.1910689.
Google Scholar | Crossref | Medline32. Singhal, D, Hahn, CN, Feurstein, S, et al. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia. Epub ahead of print 13 April 2021. DOI: 10.1038/s41375-021-01246-w.
Google Scholar | Crossref | Medline33. He, L, Liu, Y, Lai, W, et al. DNA sensors, crucial receptors to resist pathogens, are deregulated in colorectal cancer and associated with initiation and progression of the disease. J Cancer 2020; 11: 893–905.
Google Scholar | Crossref | Medline34. Qi, Z, Yan, F, Chen, D, et al. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma. Biosci Rep 2020; 40: BSR20202603.
Google Scholar | Crossref35. An, J, Luo, Z, An, W, et al. Identification of spliceosome components pivotal to breast cancer survival. RNA Biol 2021; 18: 833–842.
Google Scholar | Crossref | Medline36. Kobatake, K, Ikeda, K, Sekino, Y, et al. DDX41 expression causes deregulation of cell cycle and worse prognosis in patients with clear cell renal cell carcinoma. Cancer Sci 2021; 112: 834–834.
Google Scholar37. Berger, G, van den Berg, E, Sikkema-Raddatz, B, et al. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia 2017; 31: 520–522.
Google Scholar | Crossref | Medline38. Kobayashi, S, Kobayashi, A, Osawa, Y, et al. Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation. Leukemia 2017; 31: 1020–1022.
Google Scholar | Crossref | Medline39. Diness, BR, Risom, L, Frandsen, TL, et al. Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41. Genes Chromosomes Cancer 2018; 57: 670–674.
Google Scholar | Crossref | Medline40. Király, AP, Kállay, K, Gángó, A, et al. Familial acute myeloid leukemia and myelodysplasia in Hungary. Pathol Oncol Res 2018; 24: 83–88.
Google Scholar | Crossref | Medline41. Christiansen, M, Offersen, R, Jensen, JMB, et al. Identification of novel genetic variants in CVID patients with autoimmunity, autoinflammation, or malignancy. Front Immunol 2019; 10: 3022.
Google Scholar | Crossref | Medline42. Hosono, N, Makishima, H, Mahfouz, R, et al. Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget 2017; 8: 6483–6495.
Google Scholar | Crossref | Medline43. Jiang, Y, Zhu, Y, Liu, ZJ, et al. The emerging roles of the DDX41 protein in immunity and diseases. Protein Cell 2017; 8: 83–89.
Google Scholar | Crossref | Medline44. Greenberg, PL, Tuechler, H, Schanz, J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Google Scholar | Crossref | Medline | ISI45. Makishima, H, Nannya, Y, Takeda, J, et al. Clinical impacts of germline DDX41 mutations on myeloid neoplasms. Blood 2020; 136: 38–40.
Google Scholar | Crossref46. Kadono, M, Kanai, A, Nagamachi, A, et al. Biological implications of somatic DDX41 p .R525H mutation in acute myeloid leukemia. Exp Hematol 2016; 44: 745–754.e744.
Google Scholar | Crossref47. Ogawa, S. Genetics of MDS. Blood 2019; 133: 1049–1059.
Google Scholar | Crossref | Medline48. Welch, JS, Petti, AA, Miller, CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 2016; 375: 2023–2036.
Google Scholar | Crossref | Medline49. Fenaux, P, Mufti, GJ, Hellstrom-Lindberg, E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
Google Scholar | Crossref | Medline | ISI50. Wang, Y, Liu, QF, Xu, LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 201